A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Amgen1,000 enrolled

Overview

Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Nephrology

Interventions

Sensipar®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 3 month history of Stage 4 or Stage 5 CKD * A PTH value within 3 months of enrollment * If relevant, completion of Sensipar® study prior to enrolling in Registry Exclusion Criteria: * Females who are pregnant or breast feeding

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.